Want to see EVH full AI Analyst Report?
EVH Stock Chart & Stats
$4.59
$0.00(0.00%)
At close: 4:00 PM EDT
$4.59
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.10 - $9.63
Previous CloseN/A
Volume827.94K
Average Volume (3M)3.06M
Market Cap
$469.20M
Enterprise Value$1.44K
Total Cash (Recent Filing)$115.70M
Total Debt (Recent Filing)$970.43M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Nov 04, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.49
Shares Outstanding113,059,330
10 Day Avg. Volume2,012,846
30 Day Avg. Volume3,055,820
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.10
Price to Sales (P/S)0.24
P/FCF Ratio96.07
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.80Price Target Upside26.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)0.17
Revenue Forecast (FY)$2.62B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Contract VisibilityRaised revenue guidance indicates stronger near-term demand, while renewal of three major customers supports recurring revenue visibility. Together, these developments suggest that customer relationships and expanding program adoption can provide a durable base for growth over the next several quarters.
AI-Enabled ProductivityScaling Auth Intelligence can improve authorization speed, reduce manual workload, and enhance operating productivity without degrading clinical quality. Broader adoption may support margin recovery and strengthen Evolent’s technology differentiation as customers seek more efficient specialty-care administration.
Performance Suite ExpansionThe oncology partnership expands Evolent’s addressable membership and specialty-care footprint across multiple states. If approvals and launch plans proceed, the contract could materially increase recurring scale while deepening the company’s position in outsourced, technology-enabled clinical management.
Bears Say
Deep Profitability And Margin PressurePersistent net losses and lower gross margins show that revenue growth has not yet translated into sustainable profitability. Continued cost-of-services or mix pressure could limit internal funding capacity and make the company more dependent on successful productivity actions and execution.
High Net Leverage And Refinancing RiskHigh net debt reduces financial flexibility and leaves less capacity to absorb operating volatility or fund expansion internally. The need to address future maturities also makes capital-structure execution important, since refinancing conditions and repayment requirements could constrain strategic choices.
Membership HeadwindsLower covered membership can weaken volumes across Evolent’s delegated clinical and administrative programs, especially where revenue depends on the populations served. Medicaid contraction, exchange pressure, and client exits therefore create a structural obstacle to sustaining growth in affected markets.
Evolent Health News
EVH FAQ
What was Evolent Health’s price range in the past 12 months?
Evolent Health lowest stock price was $2.10 and its highest was $9.63 in the past 12 months.
What is Evolent Health’s market cap?
Evolent Health’s market cap is $469.20M.
When is Evolent Health’s upcoming earnings report date?
Evolent Health’s upcoming earnings report date is Nov 04, 2026 which is in 54 days.
How were Evolent Health’s earnings last quarter?
Evolent Health released its earnings results on Aug 06, 2026. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.03.
Is Evolent Health overvalued?
According to Wall Street analysts Evolent Health’s price is currently Undervalued.
Does Evolent Health pay dividends?
Evolent Health does not currently pay dividends.
What is Evolent Health’s EPS estimate?
Evolent Health’s EPS estimate is 0.06.
How many shares outstanding does Evolent Health have?
Evolent Health has 113,059,330 shares outstanding.
What happened to Evolent Health’s price movement after its last earnings report?
Evolent Health reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 16.558%.
Which hedge fund is a major shareholder of Evolent Health?
Currently, no hedge funds are holding shares in EVH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolent Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.80 (26.36% Upside)
$5.80 (26.36% Upside)
Blogger Sentiment
Bullish
EVH Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-54.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Evolent Health
Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.
EVH Company Deck
EVH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a balanced mix of strong operational execution and growth momentum (notably 31% QoQ revenue growth, a 50% jump in Performance Suite revenue, raised 2026 revenue guidance, a large oncology deal, and meaningful AI progress) alongside notable near-term challenges (elevated MER, membership headwinds from Medicaid/exchange, timing variability in EBITDA recognition, and elevated net leverage). Management expressed confidence in 2027 growth (>25% revenue) and margin recovery driven by AI, Performance Suite maturation and cost actions, but acknowledged material macro- and client-specific risks that temper near-term financial clarity.View all EVH earnings summariesEVH Stock 12 Month Forecast
Average Price Target
$5.80
▲(26.36% Upside)
Technical Analysis
Ownership Overview
2.76% Insiders
13.34% Mutual Funds
32.13% Other Institutional Investors
38.90% Public Companies and
Individual Investors